JP2009512691A - クロストリジウムディフィシレ関連の下痢の治療方法 - Google Patents

クロストリジウムディフィシレ関連の下痢の治療方法 Download PDF

Info

Publication number
JP2009512691A
JP2009512691A JP2008536608A JP2008536608A JP2009512691A JP 2009512691 A JP2009512691 A JP 2009512691A JP 2008536608 A JP2008536608 A JP 2008536608A JP 2008536608 A JP2008536608 A JP 2008536608A JP 2009512691 A JP2009512691 A JP 2009512691A
Authority
JP
Japan
Prior art keywords
mixture
compound
weight
treatment
mcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008536608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009512691A5 (fr
Inventor
シアース，パメラ
シュー，ヨウ−コン
ミラー−シャングル，スター，ルイス
ウォルシュ，ロバート，ブライアン
ババカニ，ファラー
チウ，ユー−フン
ロメロ，アレックス
ゴルバッチ，シャーウッド
ルーイ，トーマス，ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optimer Pharmaceuticals LLC
Original Assignee
Optimer Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optimer Pharmaceuticals LLC filed Critical Optimer Pharmaceuticals LLC
Publication of JP2009512691A publication Critical patent/JP2009512691A/ja
Publication of JP2009512691A5 publication Critical patent/JP2009512691A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008536608A 2005-10-21 2006-10-23 クロストリジウムディフィシレ関連の下痢の治療方法 Pending JP2009512691A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72913505P 2005-10-21 2005-10-21
US74964105P 2005-12-12 2005-12-12
PCT/US2006/041436 WO2007048059A2 (fr) 2005-10-21 2006-10-23 Méthode de traitement d'une diarrhée associée à clostridium difficile

Publications (2)

Publication Number Publication Date
JP2009512691A true JP2009512691A (ja) 2009-03-26
JP2009512691A5 JP2009512691A5 (fr) 2009-12-10

Family

ID=37963388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008536608A Pending JP2009512691A (ja) 2005-10-21 2006-10-23 クロストリジウムディフィシレ関連の下痢の治療方法

Country Status (8)

Country Link
EP (1) EP1940417A4 (fr)
JP (1) JP2009512691A (fr)
KR (1) KR101399621B1 (fr)
CN (2) CN102503994A (fr)
AU (1) AU2006304868B2 (fr)
CA (1) CA2626698C (fr)
HK (1) HK1126410A1 (fr)
WO (1) WO2007048059A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
JO3464B1 (ar) 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
CN104846044B (zh) * 2014-02-17 2019-02-01 上海医药工业研究院 一种提高非达霉素产量的发酵培养基
CN105237599B (zh) * 2015-10-09 2018-10-02 华北制药集团新药研究开发有限责任公司 闰年霉素a4晶体及其制备方法
CN107970253B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗寨卡病毒感染引起的相关疾病和/或症状的药物中的应用
CN107714713B (zh) * 2017-10-25 2020-05-26 中山大学 台勾霉素衍生物在制备治疗登革病毒感染引起的相关疾病和/或症状的药物中的应用
JP7397071B2 (ja) * 2018-06-07 2023-12-12 アルチュジェン セラピューティクス リミテッド Ｃ．ディフィシル治療方法及び組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014295A2 (fr) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Fabrication de tiacumicine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5583115A (en) * 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
SI2070530T1 (sl) * 2004-05-14 2016-05-31 Merck Sharp & Dohme Corp. Zdravljenje bolezni, povezanih z uporabo antibiotikov
MX2007009196A (es) * 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014295A2 (fr) * 2002-07-29 2004-02-19 Optimer Pharmaceuticals, Inc. Fabrication de tiacumicine
JP2005534332A (ja) * 2002-07-29 2005-11-17 オプティマー ファーマシューティカルズ、インコーポレイテッド チアクマイシン生産

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012028534; ＨＯＣＨＬＯＷＳＫＩ，Ｊ．Ｅ．　ｅｔ　ａｌ: 'Ｔｉａｃｕｍｉｃｉｎｓ，　ａ　ｎｏｖｅｌ　ｃｏｍｐｌｅｘ　ｏｆ　１８-ｍｅｍｂｅｒｅｄ　ｍａｃｒｏｌｉｄｅｓ．　ＩＩ．　Ｉｓｏｌａｔｉｏｎ　ａｎｄ　ｓｔｒｕｃｔｕｒｅ　ｄｅｔｅｒｍｉｎａｔｉｏｎ' Ｊ　Ａｎｔｉｂｉｏｔ Ｖｏｌ．４０，　Ｎｏ．５, 1987, ｐ．５７５-８８ *

Also Published As

Publication number Publication date
EP1940417A2 (fr) 2008-07-09
CN101340919B (zh) 2011-12-07
AU2006304868B2 (en) 2013-02-21
KR20080064177A (ko) 2008-07-08
EP1940417A4 (fr) 2010-07-07
HK1126410A1 (en) 2009-09-04
AU2006304868A1 (en) 2007-04-26
CA2626698A1 (fr) 2007-04-26
CN102503994A (zh) 2012-06-20
KR101399621B1 (ko) 2014-06-18
CA2626698C (fr) 2015-12-01
CN101340919A (zh) 2009-01-07
WO2007048059A3 (fr) 2007-05-31
WO2007048059A2 (fr) 2007-04-26

Similar Documents

Publication Publication Date Title
JP2009512691A (ja) クロストリジウムディフィシレ関連の下痢の治療方法
CN101128114B (zh) 18元环大环化合物及其类似物
US20140107054A1 (en) Method of treating clostridium difficile-associated diarrhea
EP2826473B1 (fr) Utilisation antibactérienne du patchoulol
EP2222309B1 (fr) Composés macrocycliques antibiotiques et leurs procédés de fabrication et d'utilisation
EP1765312B1 (fr) Traitement de maladies consecutives a un traitement antibiotique
JP2015061858A (ja) 胃腸疾患を治療するための方法
US20040147441A1 (en) Methods and reagents for preventing bacteremias
EP2500022B1 (fr) Agent antibactérien contre des bactéries pharmacorésistantes et usage associé
US20190307744A1 (en) Pharmaceutical compositions comprising clofazimine analog compound b746 or clofazimine analog compound b826
JP2961182B2 (ja) クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
WO2012050826A1 (fr) Procédés de traitement d'infections par clostridium difficile
EP2010202B1 (fr) Composés antibactériens
Singh et al. Comparing cefixime, cefpodoxime and ofloxacin as anti-microbial agents and their effects on gut microbiota
US7981859B2 (en) Glycopeptide composition with improved antibiotic activity
Katara et al. Role of bacteria and fungi in antibiotic production
CN114569590A (zh) 新鱼腥草素钠的医药用途
JP2010059057A (ja) 蛋白質毒素の分泌阻害剤
Mohammed Effect of green tea on the effectiveness of Cefixime on Escherichia coli and Pseudomonas aeruginosa bacteria
Tabouguia et al. Investigational Medicinal Chemistry and Pharmacology Journal/Investigational Medicinal Chemistry and Pharmacology/Vol. 1 No. 1 (2018)/Articles
Tabouguia et al. Plants-Drug Interactions Against Some Multi-drug Resistant Microorganisms Causing Urogenital Tract Infections in Cameroon

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120827

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130305